Budget Impact Analysis of Antiepileptic Drugs for Lennox-Gastaut Syndrome

BACKGROUND: In October 2011, clobazam was FDA-approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a debilitating childhood epilepsy characterized by drop attacks, for patients 
2 years and older. OBJECTIVES: To assess the budget impact of adding clobazam to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Skornicki, Michelle, Clements, Karen M., O’Sullivan, Amy K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437444/
https://www.ncbi.nlm.nih.gov/pubmed/24684645
http://dx.doi.org/10.18553/jmcp.2014.20.4.400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437444/
https://www.ncbi.nlm.nih.gov/pubmed/24684645
http://dx.doi.org/10.18553/jmcp.2014.20.4.400

Ejemplares similares